BGPT: Paper Review: Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes

Explore by Goal

Quick Answer Copied

Core finding (fibrosis ↔ AAV delivery)

Across 3 mouse fibrosis models, liver fibrosis reduces AAV8 (and AAV9) hepatocyte transduction, primarily via reduced vector uptake in liver (detectable within 2 days), accompanied by altered systemic clearance and extra-hepatic redistribution; meanwhile AAV-KP1 preserves transduction efficiency in fibrotic livers.

Long Answer

Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes — Paper Review

Bibliographic anchor: Nature Communications, DOI: 10.1038/s41467-025-57382-9

What the paper claims (tight logical chain)

Fibrosis reduces hepatocyte transduction/transgene expression after AAV2/8 (and AAV2/9), across multiple fibrosis etiologies and patterns (TAA, Atp7b−/−, Abcb4−/−).
The mechanism is mainly impaired vector uptake by liver cells rather than only dilution from hepatocyte proliferation, because reduced hepatic vector genomes are detectable very early (2 days post-injection) and coincides with delayed blood clearance.
Fibrosis alters biodistribution: AAV genomes redistribute toward extra-hepatic organs and toward non-parenchymal liver cells and splenic myeloid APCs.
Capsid dependence matters: a barcoded capsid library screen and individual capsid testing show that some capsids are enriched in fibrotic hepatocytes, and notably AAV-KP1 retains (or can improve) functional transduction in fibrotic livers.

Conceptual “data flow” map (from fibrosis → AAV fate)

(This diagram is an interpretation of the paper’s reported measurements; it does not add new data.)

Methodological strengths (what increases trust)

Multiple fibrosis etiologies/models reduce risk that the effect is model-specific (chemical and genetic fibrosis patterns).
Early timepoint logic: vector genome reductions are measured at 2 days (before major hepatocyte proliferation/dilution), supporting an uptake mechanism.
Cell-fraction resolution (hepatocytes vs defined NPC subsets, plus splenocyte fractions) clarifies where vector genomes accumulate.
Capsid dependence tested two ways: individual capsid validation (AAV8/9 and KP1) plus a barcoded multi-capsid screening.

Critical limitations & blind spots (what could mislead)

Mechanistic causality is suggestive, not fully proven: the paper presents uptake and biodistribution patterns consistent with impaired liver uptake and endothelial changes, but definitive mechanistic interventions (e.g., blocking specific barriers/receptors or manipulating EC fenestrations independent of fibrosis) are not provided in the supplied text.
Model-to-human extrapolation: fibrosis models differ in etiology, timing, vascular architecture, and immune context. The paper notes fibrosis exclusion in clinical trials and addresses that gap experimentally, but translation still requires human-relevant validation.
Immune consequences are incompletely resolved in the provided results: cytokine profiling is reported as not significantly upregulated at the tested dose/time window in one model, even though vector redistribution to APCs occurs. That may reflect assay sensitivity, timepoint choice, or dose effects.
Quantification caveats are acknowledged for at least one correlation analysis (GFP-positive area overestimation due to hepatocyte size changes in Atp7b−/−). This indicates that some readouts may be biased by fibrosis-associated morphology.
Vector dose and timing constraints: the paper shows reduced transduction even at higher AAV2/8 doses in fibrotic livers, but it does not fully map a dose–response surface across all capsids and fibrosis stages in the provided excerpt.

Reproducibility & data availability

Data availability: the paper states that study data are deposited in Figshare.
Replicate structure: the Methods text (as provided) states experiments are repeated independently at least two times (except AAV kit screening).
Blinding claim: investigators were blinded during data collection and analysis (noted in Methods).

What would most strongly disprove or revise the conclusions?

If a separate intervention (e.g., restoring endothelial fenestrations / vascular permeability) in fibrotic livers restored hepatocyte vector genome content and GFP without changing fibrosis independently, that would strengthen/repair the inferred uptake mechanism; failure would suggest other uptake/trafficking steps dominate.
If fibrosis-matched experiments controlling for vector pharmacokinetics (blood clearance) still show reduced hepatocyte delivery, the “clearance” explanation would be insufficient and internal processing/trafficking must be foregrounded; conversely, if normalization of clearance rescues hepatocyte transduction, then biodistribution/clearance is causal.
If KP1 does not preserve hepatocyte functional transduction under different fibrosis induction paradigms, stages, and time windows, the capsid-dependent conclusion would need revision (i.e., KP1 may work only in specific contexts).

Author review jump-links (bespoke BGPT pages)

(If any of these names are mismatched due to parsing/formatting, open the button and we can correct the author-string.)

Feedback:

Updated: April 03, 2026